Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.60 |
| ▸ | TACR1 | P25103 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342856 | 1.00 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL26303125 | 1.00 | RORC (0.60) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL23951720 | 0.88 | RORC (0.59) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL31505569 | 0.87 | RORC (0.46) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL31505546 | 0.86 | KDM4E (0.50) | RORCTACR1GPR119PDE4BKDM4E | |
| SCHEMBL6103551 | 0.86 | RORC (0.48) | RORCTACR1GPR119PDE4BUSP30 | |
| SCHEMBL6103550 | 0.86 | RORC (0.48) | RORCTACR1GPR119PDE4BUSP30 | |
| SCHEMBL2935783 | 0.84 | RORC (0.44) | RORCTACR1GPR119PDE4BNAMPT | |
| SCHEMBL2935781 | 0.84 | RORC (0.44) | RORCTACR1GPR119PDE4BNAMPT | |
| SCHEMBL23951798 | 0.83 | RORC (0.65) | RORCTACR1GPR119PDE4BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076349-B2 | Such as (3S,4S)-3-[3-(4-Methanesulfonylbenzyl)-bicyclo[3.2.1]-2,4-dioxo-1 alpha ,3,8-triaza-spiro[4.5]dodec-8-ylmethyl]-4-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester; inflammation; HIV | VIROCHEM PHARMA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-8076349-B2 | Such as (3S,4S)-3-[3-(4-Methanesulfonylbenzyl)-bicyclo[3.2.1]-2,4-dioxo-1 alpha ,3,8-triaza-spiro[4.5]dodec-8-ylmethyl]-4-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester; inflammation; HIV | VIROCHEM PHARMA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-8076349-B2 | Such as (3S,4S)-3-[3-(4-Methanesulfonylbenzyl)-bicyclo[3.2.1]-2,4-dioxo-1 alpha ,3,8-triaza-spiro[4.5]dodec-8-ylmethyl]-4-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester; inflammation; HIV | VIROCHEM PHARMA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| EP-1786815-B1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC (CA) | 2011-08-24 | — | — | EP | disclosed |
| EP-1786815-B1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC (CA) | 2011-08-24 | — | — | EP | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20090047238-A1 | Novel Spirotropane Compounds And Methods For The Modulation Of Chemokine Receptor Activity | VIROCHEM PHARMA INC. (CA) | 2009-02-19 | — | — | US | disclosed |
| US-20090047238-A1 | Novel Spirotropane Compounds And Methods For The Modulation Of Chemokine Receptor Activity | VIROCHEM PHARMA INC. (CA) | 2009-02-19 | — | — | US | disclosed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1824853-A1 | NOVEL SPIROTROPANE COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | Virochem Pharma Inc. (CA) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006060918-A1 | NOVEL SPIROTROPANE COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2006-06-15 | — | — | WO | disclosed |
| US-20060014769-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2006-01-19 | — | — | US | disclosed |
| WO-2006000096-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2006-01-05 | — | — | WO | disclosed |
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014769-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | RORC 332/4885TACR1 44/4885GPR119 249/4885 |
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CCR5, CXCR2 | RORC 139/4885TACR1 29/4885GPR119 95/4885 |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CXCR2, CXCR4 | RORC 332/4885TACR1 44/4885GPR119 249/4885 |
| US-20090047238-A1 | Novel Spirotropane Compounds And Methods For The Modulation Of Chemokine Receptor Activity | AVPR2, CCR5, CXCR1 | RORC 643/4885TACR1 16/4885GPR119 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.